Editas Medicine Announces Fourth Quarter and Full Year 2022

Commenced parallel patient dosing in the EDIT-301 RUBY trial for SCD, following clinical proof-of-concept demonstrated last quarter On track to provide...

Related Keywords

Boston ,Massachusetts ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Harvard University ,Vivo Hemoglobinopathies ,Gilmore Oneill ,Bristol Myers Squibb ,Cristi Barnett ,Ron Moldaver ,Broad Institute ,Harvard University Cas ,Health Care Conference ,Nasdaq ,Broad Institute Cas ,Business Development Other Corporate ,Exchange Commission ,Editas Medicine Inc ,Gilmoreo Neill ,Chief Executive Officer ,Sickle Cell Disease ,Editas Medicine ,Transfusion Dependent Beta Thalassemia ,Shoreline Biosciences ,Essential Gene Exon Knock In ,Betat Cells ,Myers Squibb ,Full Year ,Annual Health Care ,Private Securities Litigation Reform Act ,Annual Report ,Nasdaq Edit ,Nc ,